Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India | Zendy

TirulapatiPadmavathi Shashikala | Zendy; Julie Sachdeva | Zendy; Karthik Vinay Mahesh | Zendy; Ritu Shree | Zendy; Gaurav Jain | Zendy; A. Kapila | Zendy; ManojKumar Goyal | Zendy; Manish Modi | Zendy; Vivek Lal | Zendy

Open Access

Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India

Author(s) -

TirulapatiPadmavathi Shashikala,

Julie Sachdeva,

Karthik Vinay Mahesh,

Ritu Shree,

Gaurav Jain,

A. Kapila,

ManojKumar Goyal,

Manish Modi,

Vivek Lal

Publication year - 2020

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/ijp.ijp_333_18

Subject(s) - rituximab , myasthenia gravis , refractory (planetary science) , medicine , antibody , gastroenterology , observational study , immunology , biology , astrobiology

Approximately 10%-15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to conventional treatment. We report six patients with refractory MuSK-positive MG who responded well to the treatment with rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research